Pre-storage putrescine treatment maintains quality and prolongs postharvest life of Musa acuminata L.

The study was carried out to determine the effect of putrescine on quality and postharvest life of Musa acuminata L. during storage. The fruits were dipped at different concentrations of putrescine (0.5, 1 and 2 mM for 30 min) and distilled water as ‘control’. Changes in fruit quality attributes such as weight loss, firmness, skin color (L*, hue angle), total soluble solids (TSS), titratable acidity (TA), pH, ascorbic acid, polyphenol oxidase (PPO) and polygalacturonase (PG) enzymatic activity were calculated at harvest and after 5, 10, 15 and 20 days of storage at 0±1°C, 80-85% relative humidity. Weight loss, fruit softening, skin color changes, TSS, pH, the activity of PPO and PG increased during fruit ripening but the rate of changes was significantly slowed in putrescine treated fruits. Moreover, putrescine application maintained higher levels of TA, ascorbic acid and reduced the loss of sensory acceptability and decay incidence compared to control. In conclusion, the postharvest dip treatment of putrescine could be an effective means for extending the storage life of Musa acuminata L

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Background: Disorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021. Methods: We estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined. Findings: Globally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer. Interpretation: As the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed. Funding: Bill & Melinda Gates Foundation

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Background: Estimates of demographic metrics are crucial to assess levels and trends of population health outcomes. The profound impact of the COVID-19 pandemic on populations worldwide has underscored the need for timely estimates to understand this unprecedented event within the context of long-term population health trends. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides new demographic estimates for 204 countries and territories and 811 additional subnational locations from 1950 to 2021, with a particular emphasis on changes in mortality and life expectancy that occurred during the 2020–21 COVID-19 pandemic period. Methods: 22 223 data sources from vital registration, sample registration, surveys, censuses, and other sources were used to estimate mortality, with a subset of these sources used exclusively to estimate excess mortality due to the COVID-19 pandemic. 2026 data sources were used for population estimation. Additional sources were used to estimate migration; the effects of the HIV epidemic; and demographic discontinuities due to conflicts, famines, natural disasters, and pandemics, which are used as inputs for estimating mortality and population. Spatiotemporal Gaussian process regression (ST-GPR) was used to generate under-5 mortality rates, which synthesised 30 763 location-years of vital registration and sample registration data, 1365 surveys and censuses, and 80 other sources. ST-GPR was also used to estimate adult mortality (between ages 15 and 59 years) based on information from 31 642 location-years of vital registration and sample registration data, 355 surveys and censuses, and 24 other sources. Estimates of child and adult mortality rates were then used to generate life tables with a relational model life table system. For countries with large HIV epidemics, life tables were adjusted using independent estimates of HIV-specific mortality generated via an epidemiological analysis of HIV prevalence surveys, antenatal clinic serosurveillance, and other data sources. Excess mortality due to the COVID-19 pandemic in 2020 and 2021 was determined by subtracting observed all-cause mortality (adjusted for late registration and mortality anomalies) from the mortality expected in the absence of the pandemic. Expected mortality was calculated based on historical trends using an ensemble of models. In location-years where all-cause mortality data were unavailable, we estimated excess mortality rates using a regression model with covariates pertaining to the pandemic. Population size was computed using a Bayesian hierarchical cohort component model. Life expectancy was calculated using age-specific mortality rates and standard demographic methods. Uncertainty intervals (UIs) were calculated for every metric using the 25th and 975th ordered values from a 1000-draw posterior distribution. Findings: Global all-cause mortality followed two distinct patterns over the study period: age-standardised mortality rates declined between 1950 and 2019 (a 62·8% [95% UI 60·5–65·1] decline), and increased during the COVID-19 pandemic period (2020–21; 5·1% [0·9–9·6] increase). In contrast with the overall reverse in mortality trends during the pandemic period, child mortality continued to decline, with 4·66 million (3·98–5·50) global deaths in children younger than 5 years in 2021 compared with 5·21 million (4·50–6·01) in 2019. An estimated 131 million (126–137) people died globally from all causes in 2020 and 2021 combined, of which 15·9 million (14·7–17·2) were due to the COVID-19 pandemic (measured by excess mortality, which includes deaths directly due to SARS-CoV-2 infection and those indirectly due to other social, economic, or behavioural changes associated with the pandemic). Excess mortality rates exceeded 150 deaths per 100 000 population during at least one year of the pandemic in 80 countries and territories, whereas 20 nations had a negative excess mortality rate in 2020 or 2021, indicating that all-cause mortality in these countries was lower during the pandemic than expected based on historical trends. Between 1950 and 2021, global life expectancy at birth increased by 22·7 years (20·8–24·8), from 49·0 years (46·7–51·3) to 71·7 years (70·9–72·5). Global life expectancy at birth declined by 1·6 years (1·0–2·2) between 2019 and 2021, reversing historical trends. An increase in life expectancy was only observed in 32 (15·7%) of 204 countries and territories between 2019 and 2021. The global population reached 7·89 billion (7·67–8·13) people in 2021, by which time 56 of 204 countries and territories had peaked and subsequently populations have declined. The largest proportion of population growth between 2020 and 2021 was in sub-Saharan Africa (39·5% [28·4–52·7]) and south Asia (26·3% [9·0–44·7]). From 2000 to 2021, the ratio of the population aged 65 years and older to the population aged younger than 15 years increased in 188 (92·2%) of 204 nations. Interpretation: Global adult mortality rates markedly increased during the COVID-19 pandemic in 2020 and 2021, reversing past decreasing trends, while child mortality rates continued to decline, albeit more slowly than in earlier years. Although COVID-19 had a substantial impact on many demographic indicators during the first 2 years of the pandemic, overall global health progress over the 72 years evaluated has been profound, with considerable improvements in mortality and life expectancy. Additionally, we observed a deceleration of global population growth since 2017, despite steady or increasing growth in lower-income countries, combined with a continued global shift of population age structures towards older ages. These demographic changes will likely present future challenges to health systems, economies, and societies. The comprehensive demographic estimates reported here will enable researchers, policy makers, health practitioners, and other key stakeholders to better understand and address the profound changes that have occurred in the global health landscape following the first 2 years of the COVID-19 pandemic, and longer-term trends beyond the pandemic. Funding: Bill & Melinda Gates Foundation

Genotypic differences of olive in reproductive characteristics and fruit yield response to deficit irrigation

Water is the most important environmental factor in growth and fruit yield of trees. To study the effect of deficit irrigation on reproductive characteristics and yield of seven superior olive genotypes of D1, Dd1, Gw, Ps1, Bn3, Bn6, and Ds17. The present research was accomplished in Dallaho Olive Research Station of Sarpol-e zahab, Kermanshah, Iran, in 2014 and 2015. Seven superior olive genotypes were studied in a randomized complete block design with three replicates and three irrigation regimes. The irrigation treatments included: 100% full irrigation (control), 75% deficit irrigation, and 50% deficit irrigation applied during the growth season. The results indicated that the genotypes had different reactions to the deficit irrigation regimes. Dd1 had the highest fruit weight, while the lowest fruit weight was observed in Ps1 and Gw. The highest fruit yield was found in Bn3, Bn6, and Dd1, while the lowest was observed in Ps1. As a result, Bn6 and Dd1 are introduced as the genotypes that are resistant to drought in the field

Enhanced growth performance, oxidative capacity and immune responses of common carp, Cyprinus carpio fed with Artemisia absinthium extract-supplemented diet

In the present study, the effects of Afsanteen (Artemisia absinthium) aqueous extract (AE) were investigated on growth performance, innate immunity, and oxidative status of common carp, Cyprinus carpio. Common carp juveniles were fed experimental diets that contained 0, 0.5, 1 or 1.5% of AE for 60 days (75 fish/treatment). Thereafter, the fish growth performance, feed efficiency, serum immune-related, biochemical, and antioxidant parameters were determined. The results showed that diets containing 0.5 and 1% of AE enhanced the growth performance and feed efficiency of the fish. Fish fed with AE supplemented diets (at all concentrations) also displayed higher levels of serum lysozyme, alternative complement, total immunoglobulin, superoxide dismutase, and total protein levels compared to the control diet; the highest levels were observed at 1% AE level. Serum albumin levels of all AE-supplemented treatments were significantly higher than the control treatment. Dietary AE supplementation significantly increased plasma glutathione peroxidase activities; the highest value was related to the fish fed 0.5% AE. All AE treatments showed significantly lower serum catalase activities compared to the control; the lowest value was related to 1.5% AE. 0.5 and 1% AE significantly decreased serum malondialdehyde levels. All AE- treated fish exhibited significantly lower serum alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase activities; the lowest values were observed in 0.5% or 1% AE. In conclusion, dietary inclusions of AE in juvenile common carp increased growth performance and feed efficiency, improved the innate immunity and antioxidant response, and improved hepatic health. AE at 0.5–1% levels is recommended for common carp diet formulation. © 2021 Elsevier B.V

Ecologic study of serum selenium and upper gastrointestinal cancers in Iran

AIM: Both observational and experimental studies have shown that higher selenium status reduces the risk of upper gastrointestinal cancers in selenium deficient populations. Recent cancer registry data have shown very different rates of esophageal cancer (EC) and gastric cancer (GC) in four Provinces of Iran, namely Ardabil, Mazandaran, Golestan, and Kerman. The aim of this study was to have a preliminary assessment of the hypothesis that high rates of EC in Golestan and high rates of GC in Ardabil may be partly attributable to selenium deficiency. METHODS: We measured serum selenium in 300 healthy adults from Ardabil (n = 100), Mazandaran (n = 50), Golestan (n = 100), and Kerman (n = 50), using inductively coupled plasma, with dynamic reaction cell, mass spectrometry (ICP-DRC-MS) at the US Centers for Disease Control (Atlanta, Georgia). RESULTS: The median serum selenium concentrations were very different in the four Provinces. The medians (IQR) for selenium in Ardabil, Mazandarn, Golestan, and Kerman were 82 (75-94), 123 (111-132), 155 (141-173), and 119 (110-128) mg/L, respectively (P<0.001). The results of linear regression showed that the Province variable, by itself, explained 76% of the variance in log selenium (r2 = 0.76). The proportion of the populations with a serum selenium more than 90 mg/L (the concentration at which serum selenoproteins are saturated) was 100% in Golestan, Kerman, and Mazandaran but only 29% in Ardabil. CONCLUSION: Our findings suggest that selenium deficiency is not a major contributor to the high incidence of EC seen in northeastern Iran, but it may play a role in the high incidence of GC in Ardabil Province

Efficacy of anti-TNF therapy for the treatment of patients with moderate-to-severe inflammatory bowel disease; A first Iranian report

BACKGROUND The anti-TNF drugs are shown to be highly effective in treatment of patients with moderate-to-severe inflammatory bowel disease (IBD). Here, we aimed to assess the efficacy and safety of anti-TNF therapy at the national level. METHODS IBD patients aged 15 > years who received Infliximab and/or CinnoRA® between 2013 to July 2018 were identified. The data extracted from medical dossier and telephonic interview. The efficacy of therapy was defined as time to drug discontinuation or need for IBD-related surgery. The safety was assessed based on patient�s reported adverse events. RESULTS We included 315 patients. The mean age of patients was 37.2 years and 62.2 of them developed the disease before age 30 years. Involvement of masculoskeletal system was reported in 7.3 of patients. Partial and complete response to Anti-TNF therapy was seen in 67 of patients. About 16 of patients did not respond to induction therapy and 16.9 of patients lost their response to Anti-TNF during one year. No serious adverse events, serious opportunistic infection, tuberculosis and malignancies reported by patients. Two patients reported pneumonia. CONCLUSION This study for the first time in our country, provides the evidences for efficacy of anti-TNF therapy in moderate to severe IBD patients. © 2020 The Author(s)

Validity of continuous metabolic syndrome score for predicting metabolic syndrome; a systematic review and meta-analysis

Background: Nowadays, use of continuous metabolic syndrome (cMetS) score has been suggested to improve recognition of metabolic syndrome (MetS). The aim of this study was to evaluate the validity of cMetS scores for predicting MetS. Methods: We searched the electronic databases included MEDLINE/PubMed, Embase, ISI Web of Science, and Scopus from 1 January 1980 to 30 September 2020. Observational studies on participants with different cMetS scores were included in this meta-analysis. The sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR) and diagnostic odds ratio (DOR) with 95 CI were calculated. Results: Ten studies involving a total of 25,073 participants were included. All studies had cross-sectional design. The pooled sensitivity and specificity of cMetS scores for predicting MetS were 0.90 (95 CI: 0.83 to 0.95) and 0.86 (95 CI: 0.83 to 0.89), respectively. Moreover, cMetS scores had the pooled LR+ of 6.5 (95 CI: 5.0 to 8.6), and a pooled (LR-) of 0.11 (95 CI: 0.063 to 0.21). The pooled DOR of cMetS scores to predict MetS were 57 (95 CI: 26 to 127). Conclusions: The high sensitivity and specificity of cMetS scores indicates that it has a high accuracy to predict the risk of MetS. Furthermore, the cMetS scores has a good ability to rule out healthy people. Study registration: This study was registered as PROSPERO CRD42020157273. © 2021, Springer Nature Switzerland AG